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Abstract 
Atherosclerosis is also known as arteriosclerotic vascular disease. It is a condition when the arteries become narrowed and hardened due to the 
excessive of plaque which is made of fat, cholesterol, calcium and other substances. This study aims to examine the regulatory roles of 
triglycerides level in three distinct phases of blood pressure. One way ANOVA analysis is used to test the differences among the three distinct 
conditions, which is normal, borderline and hypertensive. The systolic blood pressure highly significant different (F (2, 997) = 3.595, p = 
0.028) across the three distinct phases. We also applied multiple linear regression (MLR) method in order to assess the associated factor of 
triglycerides level according to the three distinct phases as discussed in ANOVA analysis. The statistical analyses revealed that there are 
partially significant differences due to the different distinct phases of blood pressure.  The associated factors of triglycerides were total of 
cholesterol, high density lipoprotein cholesterol and proconvertin. All the variables were statistically significant across the three main 
conditions. These initial findings from three distinct phases denote that there a negative association between triglycerides level and HDL 
cholesterol. This finding shows that the factor of triglycerides level might be a valuable marker of atherosclerosis in three distinct phases of 
blood pressure.  
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1. introduction  
The cardiovascular disease especially in hypertension patients not only increases the risk of cardiovascular but it also increases 
the risk of atherosclerosis [1]. In epidemiologic studies, the hypertension plays the role as the one of the risk factors of 
atherosclerosis but still controversial and complex [1, 12]. This increased risk might be attributed to the heart attack, stroke, 
peripheral arterial disease, erectile dysfunction and kidney disease [16].  
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The low HDL cholesterol and high triglycerides level was one of the factors which attributed to the pathogenesis coronary artery 
disease [17]. Besides that, HDL cholesterol also helps to prevent the atherosclerotic cardiovascular complication by scavenges 
and removes LDL or bad cholesterol and act as a maintenance function for the inner walls of blood vessel [15, 18]. A strong 
association between triglycerides and HDL-cholesterol level might exist in three distinct phases of blood pressure which normal, 
borderline and hypertensive. This study aims to examine the regulatory roles of triglycerides level in three distinct phases of 
blood pressure.  
1.1. Materials and methods 
The participants are patient diagnosed clinically with triglycerides and HDL-Cholesterol with three distinct phases of normal, 
borderline and hypertensive among blood pressure patients between 1st January 2009 and 31st December 2011. A total of 1000 
registered patients from Hospital University Sains Malaysia (HUSM) were screened and met the inclusion and exclusion criteria 
(Table 1). The description of the variables also can be seen in the Table 3. 
             Table 1. Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
a) From Malay population a) Breast feeding or pregnant women 
b) Blood pressure is divided to normal 
    (<120), borderline (120-139) and 
     hypertension (>140) 
b) The presence of chronic disease such as 
    kidney disease, liver disease and serious 
    injuries 
c) Any other condition which recommend 
     by the physician 
c) Any other condition which not recommended 
     by the physician 
 
 
The main outcome evaluated is the association of the triglyceride level which was evaluated by using multiple linear regression 
analysis. All subjects were assigned to blood pressure level categories which are systolic blood pressure level which are normal, 
borderline and hypertensive.  Normal systolic blood pressure classification is less than 120 mmHg, borderline is 120-139 mmHg 
and hypertensive is more than 140 mmHg [9]. Power and Sample Size Calculation (PS) software are used to calculate sample 
size of the analysis with significance level ( )α  0.05 and the power of the study ( )β−1 of 80% [10, 11, 14, 20].  Parameter 
involved: 
• Type 1 Error = 5.0%  
• Power = 80.0% 
• M = 1  
• P0 = Based on literature review 
• P1 = Based on Expert Opinion 
The largest size sample was taken to start the analysis. From the Table 2, we choose n = 161 patients. One way analysis of 
variance (ANOVA) method were used to evaluate the triglycerides level which to test the for preferences differences among the 
three distinct phases of blood pressure. Multiple linear regression analysis with enter method was applied to serum triglyceride 
level at three distinct phases of systolic blood pressure. Two-tailed values of p were considered statistically significant which set 
at level 0.05. SPSS software version 15.0 was used to analyzed data and for all statistical calculations.  
                         Table 2. Sample Size Calculation 
 
No. Variables *P1 Po M Type 1 
error 
Power Sample 
Size 
Systolic blood pressure [18] 0.29 0.16 1 5% 80% 161 
Diastolic blood pressure [18] 0.23 0.11 1 5% 80% 153 
HDL-Cholesterol [18] 0.51 0.35 1 5% 80% 149 
Hypertension [19] 0.54 0.38 1 5% 80% 151 
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                      Table 3. Description of the variables 
Variables  Description  
Height Height (cm) 
Bmi Body mass index of patients (weight(kg)/[height(m)]2) 
Weight  Weight (kg) 
Kcal Kilo-calories of physical activity per week 
Smoke Smoking status (0 = no, 1= yes) 
Pkyrs Pack per years of smoking 
Wc Waist circumference of patients (cm) 
Hip Hip circumference (cm) 
Sbp Systolic blood pressure of patients (mmHg) 
Dbp Diastolic blood pressure of patients (mmHg) 
Triglycerides Triglycerides level of patients (mg/dl) 
Cholesterol Total cholesterol of patients (mg/dl) 
HDL-Cholesterol High density lipoprotein cholesterol (mg/dl) 
Glucose Glucose level of patients (mg/dl) 
Proconvertin Proconvertin (%) 
Fib Fibrinogen (mg/dl) 
Fhha Family history of heart attack (0 = no, 1= yes) 
Diabetes  Diabetes status (0 = no, 1= yes) 
Inccd Incident (new) CHD during 6 years of follow-up (0 = no, 1= yes) 
Insulin Insulin level of patients (IU/ml) 
Taking anti-hypertensive 
 medication 
Taking anti-hypertensive medications (0 = no, 1= yes) 
Taking lipid lowering 
 medication   
Taking lipid lowering medication (0 = no, 1= yes) 
 
 
 
            Table 4. Clinical, Lifestyle and other characteristics according to Systolic Pressure level: normal borderline 
                            and hypertensive 
 
 
Variables 
< 120 mm Hg, 
n = 232 
Mean (SD) 
120 – 139 mm Hg, 
n = 364 
Mean (SD) 
> 140 mm Hg, 
n = 398 
Mean (SD) 
Basic Data  
Height 174.03 (6.16) 174.0 (6.56) 172.46 (6.28) 
Body Mass Index 25.96 (3.80) 26.54 (3.52) 26.69 (3.76) 
Weight 48.71 (12.28) 50.48 (11.80) 49.58 (12.85) 
Lifestyle Factors  
Kilo-calories of physical activity 
per week 
2071.8 (2035.6) 
 
2235.7 (2405.8) 1957.16(2015.3) 
Smoking status 0.09 (0.284) 0.13 (0.33) 0.103 (0.304) 
Pack years of smoking 24.58 (31.37) 24.33 (27.90) 26.88 (33.30) 
Waist circumference 96.49 (10.05) 97.84 (10.07) 98.43 (10.50) 
Hip circumference 100.7 (6.82) 101.55 (6.98) 101.53 (7.98) 
Clinical factor  
Systolic blood pressure 110.42 (7.7) 129.56 (5.79) 157.73 (14.46) 
Diastolic systolic pressure 64.07 (8.51) 71.50 (8.67) 78.82 (10.50) 
Lipids  
Triglycerides 129.77 (64.82) 142.71(76.44) 147.30 (91.92) 
Total cholesterol 199.36 (39.52) 198.36 (35.09) 199.97 (34.58) 
HDL cholesterol 47.95 (11.71) 47.28 (12.05) 48.84 (13.58) 
Biochemical  
Glucose 105.17 (18.17) 109.25 (30.16) 115.93 (36.46) 
Proconvertin  110.26 (22.29) 114.0 (22.31) 117.68 (26.78) 
Fibrinogen 312.83 (61.54) 315.27 (67.98) 321.31 (66.22) 
Diseases  
Family history of heart attack 0.28 (0.451) 0.30 (0.461) 0.31 (0.462) 
Diabetes 0.239 (0.428) 0.31 (0.46) 0.372(0.48) 
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Incident coronary heart disease 0.14 (0.351) 0.14 (0.348) 0.25 (0.44) 
Medication  
Serum Insulin 16.11 (26.75) 15.98 (13.85) 17.52 (29.04) 
Taking anti-hypertensive 
medication 
0.24 (0.430) 0.33 (0.472) 
 
0.44 (0.50) 
 
Taking lipid lowering 
medication 
0.03 (0.17) 0.04 (0.20) 0.03 (0.17) 
               Note: Significant levels: **p < 0.01, *p < 0.05 
 
1.2. Results 
The risk factors characteristics according to level systolic blood pressure in normal, borderline and hypertensive are summarized 
in Table 4. Patients with higher systolic blood pressure tended to have higher triglycerides level and slightly higher of HDL-
cholesterol but total cholesterol with slightly decrease as the higher systolic blood pressure. They also had a higher intake of 
smoking pack per year; they were less physically active and also the smoker increase as the higher systolic blood pressure. They 
also tended to have a slightly low of body mass index, height and weight as the systolic blood pressure increases.  
Besides that, they also tended to higher waist and hip circumference, a higher systolic blood pressure and diastolic blood 
pressure. Furthermore, they also tended to a higher glucose, a higher proconvertin and a higher fibrinogen as the systolic blood 
pressure increases. They also tended to increase in incident coronary heart disease, family history of heart attack and diabetes as 
the high of systolic blood pressure. They also tended to take serum insulin and anti-hypertensive medication as the high systolic 
blood pressure. The taking lipid medication slightly increases and slightly decreases as the high systolic blood pressure.  
Table 5 shows the preferences for the systolic blood pressure differed significantly (F (2, 997) = 3.595, p = 0.028) across the 
three distinct phases normal, borderline and hypertensive. There are several comparisons systolic blood pressure phases listed in 
the Table 6. In the first row and second row, we can see the comparison between normal systolic blood pressure with borderline 
and normal with hypertensive systolic blood pressure. The mean difference between the two groups of systolic blood pressure is 
12.945 and 17.528. Following this row across, we see that this differences was not statistically significant (p = 0.163) followed 
by the second row which is statistically significant (p = 0.024). In the third row, comparison of borderline systolic blood pressure 
with hypertensive. The mean differences between these groups are 4.582. Following this row across, we also see that this 
differences was not statistically significant (p = 1.000). In the Table 6 above, we see that the significant overall ANOVA we 
found earlier was due to differences between just two groups: normal versus hypertensive. None of the other comparisons are 
significant.  
 
        Table 5. Results of one-way ANOVA analysis 
 
Groups Sum of squares Df Mean square F Sig. 
Between groups 46660.560 2 23330.280 3.595 0.028* 
Within groups 6471061.591 997 6490.533   
Total 6517722.151 999    
                               Notes: Dependent variable: Serum triglycerides level; Factors: Systolic blood pressure; 
                               *Significant at the 0.05 percent level. 
        
 
                          Table 6. Multiple Comparisons (Post Hoc Tests) 
 
Systolic Blood 
Pressure 
Systolic Blood 
Pressure 
Mean Difference 
(I-J) 
Std. Error Sig. 
Normal Borderline -12.945 6.716 0.163 
 Hypertensive -17.528* 6.601 0.024 
     
Borderline Normal 12.945 6.716 0.163 
 Hypertensive 4.582 5.843 1.000 
     
Hypertensive Normal 17.528* 6.601 0.024 
 Borderline 4.582 5.843 1.000 
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Table 7 shows the variables in the final model of multiple linear regression for normal blood pressure phases on triglycerides 
levels (mg/dl). The main factor which associated with triglycerides level were height, body mass index, hip circumference, total 
cholesterol, HDL cholesterol, proconvertin and incident coronary heart disease. It is clearly observed from the results that height 
(β = 1.639, 95% CL = 0.640, 2.731 p-value < 0.01), body mass index (β = 10.752, 95% CL = 5.235, 16.269 p-value < 0.01), total 
cholesterol (β = 0.420, 95% CL = 0.227, 0.614 p-value < 0.01), proconvertin (β = 0.572, 95% CL = 0.241, 0.904 p-value < 0.01), 
were positively associated with triglycerides level. Hip circumference (β = -4.151, 95% CL = -6.335, -1.968 p-value < 0.01), 
HDL cholesterol (β = -2.373, 95% CL = -3.018, -1.797 p-value < 0.01), incident coronary heart disease (β = -21.820, 95% CL = -
41.567, -2.072 p-value < 0.05), has been negatively associated with the triglycerides level. 
 
Table 8 shows the variables in the final model of multiple linear regression for borderline blood pressure phases on triglycerides 
levels (mg/dl). The main factor which associated with triglycerides level was weight, waist circumference, total cholesterol, HDL 
cholesterol, glucose and proconvertin. It is clearly observed from the results that waist circumference (β = 1.524, 95% CL = 
0.190, 2.858 p-value < 0.05), total cholesterol (β = 0.248, 95% CL = 0.068, 0.428 p-value < 0.01), glucose (β = 0.561, 95% CL = 
0.281, 0.841 p-value < 0.01), proconvertin (β = 1.123, 95% CL = 0.842, 1.403 p-value < 0.01), serum insulin (β = 0.580, 95% 
CL = 0.095, 1.065 p-value < 0.05), taking lipid lowering medication (β = 0.580, 95% CL = 0.095, 1.065 p-value < 0.05), were 
positively associated with triglycerides level. Weight (β = -1.261, 95% CL = -2.417, -0.104 p-value < 0.05) and HDL cholesterol 
(β = -2.805, 95% CL = -3.337, -2.273 p-value < 0.01), were negatively associated with the triglycerides level. 
         Table 7. Model of associated factor for Triglycerides by Multiple Linear Regression (MLR)  
                                         for Normal phases of blood pressure 
 
Variable Std. 
Coefficient 
Beta ( )β  
95.0% Confidence 
Interval For B 
p-value 
Lower        Upper 
Basic Data  
Height 1.639** 0.640 2.731 0.001 
Body Mass Index 10.752** 5.235 16.269 0.000 
Weight -0.566 -1.840 0.707 0.382 
Lifestyle Factors  
Kilo-calories of physical activity 
per week 
-0.001 
 
-0.005 0.002 0.479 
Smoking status 6.253 -18.715 31.222 0.622 
Pack years of smoking 0.032 -0.203 0.266 0.791 
Waist circumference -0.401 -1.973 1.171 0.616 
Hip circumference -4.151** -6.335 -1.968 0.000 
Clinical factors  
Systolic blood pressure 0.328 -0.575 1.231 0.475 
Diastolic systolic pressure -0.513 -1.355 0.330 0.232 
Lipid  
Total cholesterol 0.420** 0.227 0.614 0.000 
HDL cholesterol -2.373** -3.018 -1.797 0.000 
Biochemical  
Glucose 0.321 -0.343 0.986 0.342 
Proconvertin  0.572** 0.241 0.904 0.001 
Fibrinogen -0.053 -0.166 0.060 0.357 
Diseases  
Family history of heart attack -9.923 -25.452 5.606 0.209 
Diabetes 6.740 -31.356 44.836 0.728 
Incident coronary heart disease -21.820* -41.567 -2.072 0.031 
Medication  
Serum Insulin 0.037 -0.239 0.313 0.794 
Taking anti-hypertensive 
 medication 
11.924 -4.637 
 
28.486 0.157 
 
Taking lipid lowering 
 medication   
-35.963 -76.617 4.691 0.083 
R2 0.888 
Adjust R2 0.877 
Durbin-Watson                              1.867 
                     Note: Significant levels: **p < 0.01, *p < 0.05 
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Table 9 shows the variables in the final model of multiple linear regression for hypertension blood pressure phases on 
triglycerides levels (mg/dl). The main factor which associated with triglycerides level was total cholesterol, HDL cholesterol, 
proconvertin, serum insulin and taking anti-hypertensive drug. It is clearly observed from the results that total cholesterol (β = 
0.577, 95% CL = 0.346, 0.807 p-value < 0.01), proconvertin (β = 0.842, 95% CL = 0.546, 1.139 p-value < 0.01), serum insulin 
(β = 0.475, 95% CL = 0.200, 0.750 p-value < 0.01), taking anti-hypertensive drug (β = 15.704, 95% CL = 0.111, 31.297 p-value 
< 0.05), were positively associated with triglycerides level. HDL cholesterol (β = -2.962, 95% CL = -3.532, -2.393 p-value < 
0.01), were negatively associated with the triglycerides level. 
1.3. Discussion 
This paper is to examine the regulatory roles of triglycerides level in three distinct phases of blood pressure. Multiple linear 
regression models were used to identify the factors that are associated with triglycerides in normal, borderline and hypertensive 
blood pressure. Finding from the present study found that there are three factors which are significantly across three distinct 
phases of blood pressure: normal, borderline and hypertensive (see Table 7, Table 8 and Table 9). Total cholesterol, HDL 
cholesterol and proconvertin were main significant factor across the different blood pressure phases.  
 
 
 
Previous study reported by Egger et al. [6] total cholesterol remains statistically significant (p < 0.05) as a risk factor in all 
models. In another study reported that total cholesterol was increased significantly as the systolic blood pressure increased in 
both sexes [7]. Besides that, previous study by Lindeberg et al. [8] reported that a negative association was found between 
triglycerides and HDL cholesterol in Kitava and Sweden. On contrast finding on Swedish subjects, triglycerides and HDL 
cholesterol were not associated with waist circumference, glucose, BMI, insulin or systolic blood pressure in the Kitavans [8]. 
Furthermore, triglycerides were negatively associated with HDL cholesterol and positively associated with non-HDL cholesterol 
[8].  
                           Table 8. Model of associated factor for Triglycerides by Multiple Linear Regression (MLR)  
                           for borderline phases of blood pressure. 
 
Variable Std. Coefficient 
Beta ( )β  
95.0% Confidence 
Interval For B 
p-value 
   Lower        Upper 
Basic Data  
Height 0.157 -0.834 1.148 0.756 
Body Mass Index 1.578 -3.431 6.587 0.536 
Weight -1.261* -2.417 -0.104 0.033 
Lifestyle Factors  
Kilo-calories of physical activity 
per week 
-2.10×10-5 -0.003 0.003 0.987 
Smoking status 10.858 -9.051 30.767 0.284 
Pack years of smoking -0.086 -0.326 0.154 0.483 
Waist circumference 1.524* 0.190 2.858 0.025 
Hip circumference -0.388 -2.253 1.477 0.683 
Clinical factors  
Systolic blood pressure -0.643 -1.689 0.403 0.228 
Diastolic systolic pressure 0.380 -0.338 1.099 0.299 
Lipid  
Total cholesterol 0.248** 0.068 0.428 0.007 
HDL cholesterol -2.805** -3.337 -2.273 0.000 
Biochemical  
Glucose 0.561** 0.281 0.841 0.000 
Proconvertin  1.123** 0.842 1.403 0.000 
Fibrinogen -0.088 -0.183 0.007 0.068 
Diseases  
Family history of heart attack -5.718 -18.590 7.154 0.383 
Diabetes -18.082 -43.266 7.102 0.159 
Incident coronary heart disease -5.429 -23.009 12.151 0.544 
Medication  
Serum Insulin 0.580* 0.095 1.065 0.019 
Taking anti-hypertensive 1.304 -11.563 14.171 0.842 
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 medication  
Taking lipid lowering 
 medication   
38.301* 7.490 69.113 0.015 
R2 0.887 
Adjust R2 0.880 
Durbin-Watson  2.051 
                          Note: Significant levels: **p < 0.01, *p < 0.05 
 
Present study also shows that body mass index for hypertensive blood pressure was not significant. According to the Tesfaye et 
al. [21] risk of hypertension based on Ethiopia (OR = 2.47, 95% CI (1.42, 4.29)) and Vietnam (OR = 2.67, 95% CI (1.75, 4.08)) 
significantly high on body mass index. Previous study also reported that body mass index is strongly associated with HDL 
cholesterol and diabetes mellitus among heart disease patients [13]. However, this all report was not support with our finding 
results about body mass index.   
 
Serum insulin for borderline and hypertensive blood pressure was statistically significant where for normal blood pressure was 
not significant.  Previous studies also show that the insulin was significant to blood pressure and play a major role in the 
regulation of blood pressure [22]. It also reported by Falkner et al. [4] which insulin also significant in borderline blood pressure 
and there is a relation between insulin and blood pressure. Another study reported that the insulin levels were higher in 
hypertensive subject and significant positive correlation was found between insulin level and blood pressure [16].  
Present study glucose was significant for borderline blood pressure however does not significant for normal and hypertensive. 
The previous report also shows that normal blood pressure have less often had fasting blood glucose odd ratio (OR 0.4, 95% Cl: 
0.26-0.75) [12]. Henry et al [5] reported in the presence of moderate systolic hypertension can identify subject with glucose level 
which support our finding result. 
 
 
                      Table 9. Model of associated factor for Triglycerides by Multiple Linear Regression (MLR)  
                         for Hypertension phases of blood pressure 
  
Variable Std. Coefficient 
Beta ( )β  
95.0% Confidence 
Interval For B 
p-value 
   Lower        Upper 
Basic Data     
Height -0.357 -1.218 0.504 0.415 
Body Mass Index 1.934 -3.628 7.496 0.495 
Weight -1.122 -2.501 0.257 0.110 
Lifestyle Factors     
Kilo-calories of physical activity 
per week 
9.718×10-5 
 
-0.004 0.004 0.959 
 
Smoking status -2.946 -30.342 24.450 0.833 
Pack years of smoking -0.012 -0.261 0.238 0.927 
Waist circumference 0.293 -1.343 1.928 0.725 
Hip circumference 0.256 -1.732 2.244 0.800 
Clinical factors     
Systolic blood pressure  0.525 -0.014 1.064 0.056 
Diastolic systolic pressure -0.037 -0.779 0.704 0.921 
Lipid     
Total cholesterol 0.577** 0.346 0.807 0.000 
HDL cholesterol -2.962** -3.532 -2.393 0.000 
Biochemical     
Glucose 0.146 -0.161 0.452 0.351 
Proconvertin  0.842 0.546 1.139 0.000 
Fibrinogen -0.070 -0.187 0.048 0.248 
Diseases     
Family history of heart attack -3.423 -19.359 12.513 0.673 
Diabetes 3.636 -22.822 30.093 0.787 
Incident coronary heart disease -4.057 -21.337 13.224 0.645 
Medication     
Serum Insulin 0.475** 0.200 0.750 0.001 
Taking anti-hypertensive 15.704* 0.111 31.297 0.048 
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 medication   
Taking lipid lowering 
 medication   
17.221 -26.836 61.279 0.443 
R2 0.831 
Adjust R2 0.822 
Durbin-Watson  2.082 
                            Note: Significant levels: **p < 0.01, *p < 0.05 
Based on R2 value on Table 7, 8 and 9, the value of R2 were 88.8%, 88.7%, 83.1% of the variation in the triglycerides is 
explained by the independent variables. These three models appear to be very useful and benefit to make prediction since the 
value R2 is closer to 1. The Durbin-Watson estimates ranges from zero to four. If Durbin- Watson value 0 < d < 1.5 near zero 
shows strong positive autocorrelations and value 2.5 < d < 4 near four show strong negative autocorrelation. Value between 1.5 < 
d < 2.5 shows no autocorrelation. Our present study shows that all of model is range between 1.5 < d < 2.5 (see table 7, table 8 
and table 9). Hence the assumption of the independent all of three models normal, borderline and hypertensive is satisfied. In 
conclusion, this study demonstrated that triglycerides level is strongly associated with the HDL cholesterol level among normal, 
borderline and hypertensive systolic blood pressure. Hence, triglycerides level might be a valuable marker to be monitored in 
normal, borderline and hypertensive systolic blood pressure. 
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